Author Reply: Is the HBsAg response to RO7062931 an antisense effect?

Cynthia Wat,Edward Gane,Man-Fung Yuen,Vedran Pavlovic,Henrik Mueller,Ben Fillippo Krippendorff,Joseph F. Grippo, S Ottosen

Hepatology（2021）

引用 1|浏览3

暂无评分

摘要

Firstly, Dr Vaillant proposes RO7062931 should have exhibited greater HBsAg reductions, given the efficient RO7062931 liver uptake, rapid turnover of HBsAg, and rapid protein reductions observed with GalNAc-ASOs in other therapeutic indications. We find this reasoning unsatisfactory, primarily as there should be no expectations of similar potency for GalNAc-ASOs targeting different mRNA species.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要